Bittium will publish its H1'26 report on August 7. Publicly announced orders during Q2'26 totalled €...
Pentixapharm sits at the intersection of a high-prevalence indication and one of the fastest- growin...
Organic growth was above our Q2 forecast, but the company has recently faced some profitability issu...
Aktia reported positive momentum on both NII and AUM flows.
Redeye updates its Q1 2026/2027e estimates ahead of the Q1 results, due on 5 August.
* Transaction activity picking up, while FX supports AUM * Limited estimate revisions ahead of Q2 * ...
Intervacc has submitted a Type II variation application to the EMA seeking a 12-month duration of im...
Redeye gives an initial comment on the Q2 royalties for Leqembi.
Profitability (adj. EBITA margin) was weaker than we forecasted for Q2.
Withdrawn Red Cat approach underlines USV as a core growth market.
Yesterday, INDUS significantly hiked its guidance in expectation of an exceptional Q2 result, given ...
While the initial order is small, we believe the strategic significance is greater than the near-ter...
Ahead of Relais' Q2 report, we include the tershine acquisition in our estimates and take a slightly...
BB Biotech delivered a strong Q2 performance, with NAV outperforming the Nasdaq Biotech Index (NBI) ...
Redeye provides its initial take on GBK's Q2 report, which showed both topline and EBIT coming in ah...
GFT reports H1 results on 6 August, and we expect a second consecutive quarter of adj.
Market sentiment in the dry bulk shipping sector improved somewhat in Q2.
Bittium had an active Q2 in terms of announcements, including several deals from its existing client...
Relais is acquiring 70% of vehicle care company tershine from its founder and entrepreneur who will ...
INDUS is scheduled to release its H1 report on August 12th.
